THERAPEUTIC EFFICACY OF RESIQUIMOD ON TREATING CHRONIC TOXOPLASMOSIS IN EXPERIMENTAL INFECTED MICE | ||
| Journal of the Egyptian Society of Parasitology | ||
| Article 15, Volume 53, Issue 3, December 2023, Pages 537-546 PDF (1.78 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/jesp.2023.331739 | ||
| Authors | ||
| REHAM M. BRAKAT1; NAHLA M. BADR2; SHAIMAA S. SOLIMAN3; SHAIMAA A. SHARAF-EL-DEEN1 | ||
| 1Department of Parasitology | ||
| 2Department of Pathology and Public health | ||
| 3Department of Community Medicine, Faculty of Medicine, Menoufia University, Egypt | ||
| Abstract | ||
| Toxoplasmosis is a zoonotic protozoan infectious disease affects people worldwide with a high rate of morbidity and mortality. The incomplete efficacy of the approved drugs for the chronic Toxoplasma gondii infections endangers one-third of the global humans and animals with reactivation. This is due to the risky complications chronic toxoplasmosis causes. This study evaluated the TLRs 7/8 agonist, Resiquimod® for treating chronic toxoplasmosis in BALB/c mice infected with the ME49 strain of T. gondii as compared the traditionally used Pyrimethamine ® & Sulphadiazine®. This was judged by the number of brain cysts, the histpathological degrees in the brain and retina, expression of the apoptotic marker, caspase-3 compared to negative and positive controls. The results showed a statistically significant decrease in the number of brain cysts in resiquimod- treated mice correlated with the histopathological improvement of brain and retina and apoptosis. | ||
| Keywords | ||
| T. gondii; Mice; Pyrimethamine; Sulphadiazine TLR7/8 agonist; Resiquimod | ||
|
Statistics Article View: 156 PDF Download: 294 |
||
